ロード中...
Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer
BACKGROUND: National Comprehensive Cancer Network guidelines recommend monthly osteoclast inhibitor treatment (OIT) in men with metastatic castration-resistant prostate cancer (mCRPC) to prevent skeletal related events (SREs). We assessed adherence to guidelines by quantifying treatment for SRE prev...
保存先:
| 出版年: | Clin Oncol Res |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6457685/ https://ncbi.nlm.nih.gov/pubmed/30984916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31487/j.COR.2018.03.001 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|